Note | |
| |
Entity | Gastrointestinal stromal tumor (GIST) |
Note | Activating mutations of PDGFRA are found in 5-8% of patients with gastrointestinal stromal tumors (GISTs) but their frequency increases to 30% to 40% in gastric GISTs lacking KIT mutations (Corless et al., 2005; Lasota et al., 2008). The majority of these mutations are "substitution missense", that can arise by various mechanisms (Figure 1). These include mutation hot spots in exon 18 of the PDGFRA gene such as the Asp-to-Val substitution at codon 842 (D842V) encoding the activation loop. Other activating mutations are less frequent such as mutations in exons 12 encoding the juxtamembrane domain and in exon 14 encoding the tyrosine kinase 1 domain of PDGFRA (Chompret et al., 2004; Heinrich et al., 2003). PDGFRA mutations except for D842V in exon 18 are sensitive to imatinib inhibition. However, despite initial clinical responses to tyrosine kinase inhibitors (imatinib, nilotinib, sorafenib and sunatinib), the majority of these patient develops resistance to the drug limiting the long-term benefit of tyrosine kinase inhibitors in this group of patients (Gramza et al., 2009; Pierotti et al., 2011). The D842V mutation results in an amino acid substitution at position 842 in PDGFRA, from an aspartic acid (D) to a valine (V). This mutation occurs within the TK2 domain (Figure 1). PDGFRA D842V mutation has been found in a distinct subset of GIST, typically from the stomach. The D842V mutation is known to be associated with tyrosine kinase inhibitor resistance. |
|  |
| |
| Figure 1. Schematic representation of the most frequent activating mutations of the homologous platelet-derived growth factor receptor alpha (PDGFRA) kinase in patients with gastrointestinal stromal tumors. Most common mutations are in exon 18, such as the D842V substitution that shows resistance to imatinib. Mutations in the juxtamembrane domain (exon 12; V561D most common) and in exon 14 tyrosine kinase 1 (TK1) domain (e.g., N659K) are less common. Abbreviations: JM, juxtamembrane; TK, tyrosine kinase. Adopted and modified from Pierott et al., 2011). |
| |
| |
| |
Entity | Hematologic disorders with primary eosinophilia |
Note | Several chromosomal rearrangements generating fusion genes causing PDGFRA activation have been described in a variety of uncommon hematologic disorders that are often accompanied with a related condition called hypereosinophilic syndrome. These rearrangements activate PDGFRA by fusion to various partner genes: STRN (2p24) in the t(2;4)(p22;q12), FIP1L1 (interstitial 4q12 deletion), CDK5RAP2 (9q33) in the ins(9;4)(q33;q12q25), KIF5B (10p11) in the t(4;10)(q12;p11), ETV6 (12p13) in the t(4;12)(q12;p13), and BCR (22q11) in the t(4;22)(q12;q11). In each of these rearrangements, the breakpoints in PDGFRA partner genes are variable, but the breakpoints in PDGFRA invariably involve exon 12 encoding a portion of the juxtamembrane domain with autoinhibitory function (Baxter et al., 2002; Gotlib et al., 2008); the disruption of which activates the fusion protein (Figure 2). The most investigated of these fusion genes is FIP1L1-PDGFRA that arise as a result of a cryptic interstitial deletion on chromosome 4q12. FIP1L1-PDGFRA fusion protein is involved in the pathogenesis of uncommon hematologic disorders with primary eosinophilia like chronic eosinophilic leukemia (CEL) hyperseosinophilic syndrome (HES) and systemic mastocytosis (SM). Similar to other fusion tyrosine kinases, FIP1L1-PDGFRA is a constitutively active tyrosine kinase that was shown to be sensitive to kinase inhibitors (Cools et al., 2003; Jain et al., 2013). |
|  |
| |
| Figure 2. The structure and mechanism of activation of PDGFRA fusions in hematological disorders. In the fusion oncogene, the partner gene always replaces the 5 part of exon 12 of PDGFRA creating an in frame fusion. As the 5 part of exon 12 of PDGFRA containing the inhibitory domain is truncated, its expression is controlled by the partner gene promoter resulting in constitutive activation of the PDGFRA kinase domain. NH2: N-terminal site; COOH: C-terminal site; TM: transmembrane domain; JM: juxtamembrane domain. Adopted and modified from Cools et al., 2003 and Gotlib et al., 2008). |
| |
| |
Entity | Lung adenocarcinoma |
Cytogenetics | A t(4;12)(q12;q12) was found in a case of lung adenocarcinoma (Seo et al., 2012). |
Hybrid/Mutated Gene | SCAF11/PDGFRA |
| |
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. |
Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NC. |
Hum Mol Genet. 2002 Jun 1;11(12):1391-7. |
PMID 12023981 |
|
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. |
Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, Lenoir GM, Bressac-De Paillerets B. |
Gastroenterology. 2004 Jan;126(1):318-21. |
PMID 14699510 |
|
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. |
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. |
N Engl J Med. 2003 Mar 27;348(13):1201-14. |
PMID 12660384 |
|
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. |
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. |
J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. (REVIEW) |
PMID 15928335 |
|
Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. |
Demoulin JB, Montano-Almendras CP. |
Am J Blood Res. 2012;2(1):44-56. Epub 2012 Jan 1. |
PMID 22432087 |
|
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. |
Gotlib J, Cools J. |
Leukemia. 2008 Nov;22(11):1999-2010. doi: 10.1038/leu.2008.287. Epub 2008 Oct 9. (REVIEW) |
PMID 18843283 |
|
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. |
Gramza AW, Corless CL, Heinrich MC. |
Clin Cancer Res. 2009 Dec 15;15(24):7510-7518. |
PMID 20008851 |
|
The human PDGF receptor alpha-subunit gene maps to chromosome 4 in close proximity to c-kit. |
Gronwald RG, Adler DA, Kelly JD, Disteche CM, Bowen-Pope DF. |
Hum Genet. 1990 Aug;85(3):383-5. |
PMID 1697560 |
|
PDGFRA activating mutations in gastrointestinal stromal tumors. |
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. |
Science. 2003 Jan 31;299(5607):708-10. Epub 2003 Jan 9. |
PMID 12522257 |
|
Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. |
Heldin CH, Lennartsson J. |
Cold Spring Harb Perspect Biol. 2013 Aug 1;5(8):a009100. doi: 10.1101/cshperspect.a009100. (REVIEW) |
PMID 23906712 |
|
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. |
Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. |
Blood. 2013 Nov 7;122(19):3387-8. doi: 10.1182/blood-2013-07-516500. |
PMID 24203930 |
|
Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. |
Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T. |
Genomics. 1995 Nov 20;30(2):224-32. |
PMID 8586421 |
|
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. |
Lasota J, Miettinen M. |
Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. (REVIEW) |
PMID 18312355 |
|
Targeted therapy in GIST: in silico modeling for prediction of resistance. |
Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. |
Nat Rev Clin Oncol. 2011 Mar;8(3):161-70. doi: 10.1038/nrclinonc.2011.3. (REVIEW) |
PMID 21364689 |
|
The transcriptional landscape and mutational profile of lung adenocarcinoma. |
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT. |
Genome Res. 2012 Nov;22(11):2109-19. |
PMID 22975805 |
|